T D Szucs

Summary

Affiliation: University of Basel
Country: Switzerland

Publications

  1. ncbi The use of the EVITA algorithm for clinical assessment of novel agents used in prostate cancer, metastatic melanoma, and systemic lupus erythematosus
    Thomas D Szucs
    Institute of Pharmaceutical Medicine ECPM, University of Basel, Klingelbergstrasse 61, 4056, Basel, Switzerland
    Eur J Clin Pharmacol 70:983-90. 2014
  2. doi A systematic review of the cost effectiveness of herpes zoster vaccination
    Thomas D Szucs
    Institute of Pharmaceutical Medicine European Center of Pharmaceutical Medicine ECPM, University of Basel, Klingelbergstrasse 61, 4056, Basel, Switzerland
    Pharmacoeconomics 31:125-36. 2013
  3. pmc Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery
    Matthias Schwenkglenks
    Institute of Pharmaceutical Medicine, University of Basel, Basel, Switzerland
    J Hematol Oncol 3:27. 2010
  4. pmc Reconstruction versus conservative treatment after rupture of the anterior cruciate ligament: cost effectiveness analysis
    Mazda Farshad
    Department of Orthopedic Surgery, University of Zurich, Balgrist University Hospital, Zurich, Switzerland
    BMC Health Serv Res 11:317. 2011
  5. pmc Determining utility values in patients with anterior cruciate ligament tears using clinical scoring systems
    Mazda Farshad
    Balgrist University Hospital, Orthopedic Surgery, University of Zurich, Switzerland
    BMC Health Serv Res 11:182. 2011
  6. pmc Diagnostic accuracy of point-of-care testing for acute coronary syndromes, heart failure and thromboembolic events in primary care: a cluster-randomised controlled trial
    Yuki Tomonaga
    European Center of Pharmaceutical Medicine, University of Basel, 4051 Basel, Switzerland
    BMC Fam Pract 12:12. 2011
  7. pmc Cost-effectiveness of oral alitretinoin in patients with severe chronic hand eczema--a long-term analysis from a Swiss perspective
    Patricia R Blank
    ECPM Institute of Pharmaceutical Medicine, University of Basel, Klingelbergstrasse 61, 4056 Basel, Switzerland
    BMC Dermatol 10:4. 2010
  8. ncbi [Cost-effectiveness of atorvastatin for the prevention of coronary disease. An analysis of the ASCOT study]
    T D Szucs
    ECPM Research, University Hospital, Basel
    Dtsch Med Wochenschr 129:1420-4. 2004
  9. ncbi Cost-effectiveness studies in ovarian cancer
    T D Szucs
    Hirslanden Research, Division of Gynecology, University Hospital, Zurich, Switzerland
    Int J Gynecol Cancer 13:212-9. 2003
  10. doi Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia
    T D Szucs
    Institute of Pharmaceutical Medicine, University of Basel, Basel, Switzerland
    Oncology 81:45-9. 2011

Collaborators

Detail Information

Publications26

  1. ncbi The use of the EVITA algorithm for clinical assessment of novel agents used in prostate cancer, metastatic melanoma, and systemic lupus erythematosus
    Thomas D Szucs
    Institute of Pharmaceutical Medicine ECPM, University of Basel, Klingelbergstrasse 61, 4056, Basel, Switzerland
    Eur J Clin Pharmacol 70:983-90. 2014
    ..We therefore sought to use EVITA to evaluate eight novel agents recently introduced to clinical practice or in late-stage trials for the treatment of prostate cancer, metastatic melanoma, or systemic lupus erythematosus (SLE)...
  2. doi A systematic review of the cost effectiveness of herpes zoster vaccination
    Thomas D Szucs
    Institute of Pharmaceutical Medicine European Center of Pharmaceutical Medicine ECPM, University of Basel, Klingelbergstrasse 61, 4056, Basel, Switzerland
    Pharmacoeconomics 31:125-36. 2013
    ..Whereas chickenpox infections are normally mild but common among children, HZ infections are common among elderly people and can give rise to post-herpetic neuralgia (PHN), a severe and painful complication...
  3. pmc Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery
    Matthias Schwenkglenks
    Institute of Pharmaceutical Medicine, University of Basel, Basel, Switzerland
    J Hematol Oncol 3:27. 2010
    ..The aim of this analysis was to assess the impact of chemotherapy-induced neutropenia (CIN) on ABVD chemotherapy delivery in HL patients...
  4. pmc Reconstruction versus conservative treatment after rupture of the anterior cruciate ligament: cost effectiveness analysis
    Mazda Farshad
    Department of Orthopedic Surgery, University of Zurich, Balgrist University Hospital, Zurich, Switzerland
    BMC Health Serv Res 11:317. 2011
    ..A critical evaluation of benefits and expenditures of both treatment options as in a cost effectiveness analysis seems well-suited to provide valuable information for treating physicians and healthcare policymakers...
  5. pmc Determining utility values in patients with anterior cruciate ligament tears using clinical scoring systems
    Mazda Farshad
    Balgrist University Hospital, Orthopedic Surgery, University of Zurich, Switzerland
    BMC Health Serv Res 11:182. 2011
    ..These values will be used for the interpretation and comparison of outcome results in the currently available literature for different treatment options...
  6. pmc Diagnostic accuracy of point-of-care testing for acute coronary syndromes, heart failure and thromboembolic events in primary care: a cluster-randomised controlled trial
    Yuki Tomonaga
    European Center of Pharmaceutical Medicine, University of Basel, 4051 Basel, Switzerland
    BMC Fam Pract 12:12. 2011
    ..The aim of this study is to analyse the diagnostic accuracy of POCT in primary care...
  7. pmc Cost-effectiveness of oral alitretinoin in patients with severe chronic hand eczema--a long-term analysis from a Swiss perspective
    Patricia R Blank
    ECPM Institute of Pharmaceutical Medicine, University of Basel, Klingelbergstrasse 61, 4056 Basel, Switzerland
    BMC Dermatol 10:4. 2010
    ..We assessed the cost-effectiveness of alitretinoin for CHE patient treatment from a Swiss third party payer perspective. A further objective of this study was to determine the burden of disease in Switzerland...
  8. ncbi [Cost-effectiveness of atorvastatin for the prevention of coronary disease. An analysis of the ASCOT study]
    T D Szucs
    ECPM Research, University Hospital, Basel
    Dtsch Med Wochenschr 129:1420-4. 2004
    ....
  9. ncbi Cost-effectiveness studies in ovarian cancer
    T D Szucs
    Hirslanden Research, Division of Gynecology, University Hospital, Zurich, Switzerland
    Int J Gynecol Cancer 13:212-9. 2003
    ..Nevertheless, patients' quality of life must be considered when making a clinical decision to treat this disease. A review of available cost-effectiveness studies is presented and discussed...
  10. doi Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia
    T D Szucs
    Institute of Pharmaceutical Medicine, University of Basel, Basel, Switzerland
    Oncology 81:45-9. 2011
    ..The economic implications of adding i.v. iron to ESA treatment are less well investigated. Published randomized controlled trials do not provide sufficient data for a comprehensive cost-effectiveness analysis...
  11. pmc Cost-effectiveness of antihypertensive treatment in patients 80 years of age or older in Switzerland: an analysis of the HYVET study from a Swiss perspective
    T D Szucs
    Department of Medical Economics, Institute of Social and Preventive Medicine, University of Zurich, Zurich, Switzerland
    J Hum Hypertens 24:117-23. 2010
    ..Moreover, considering that antihypertensive treatment also positively affects the incidence of dementia, those net benefits might even be underestimated...
  12. doi Trastuzumab beyond progression: a cost-utility analysis
    K W Matter-Walstra
    European Center of Pharmaceutical Medicine, University of Basel, Basel, Switzerland
    Ann Oncol 21:2161-8. 2010
    ..The continuation of trastuzumab beyond progression in combination with capecitabine as secondary chemotherapy for HER2-positive metastatic breast cancer (MBC) prolongs progression-free survival without a substantial increase in toxicity...
  13. doi Disparities in influenza vaccination coverage rates by target group in five European countries: trends over seven consecutive seasons
    P R Blank
    Institute of Social and Preventive Medicine, University of Zurich, Zurich, Switzerland
    Infection 37:390-400. 2009
    ..An additional aim was to analyze coverage trends over seven consecutive seasons and to gain an understanding of the primary drivers and barriers to immunization...
  14. doi Balancing costs and benefits in cancer therapy and prevention
    T D Szucs
    Institute of Social and Preventive Medicine, University of Zurich, Zurich, Switzerland
    Ann Oncol 19:vii313-9. 2008
  15. ncbi Pharmacoeconomics of anticoagulation therapy for stroke prevention in atrial fibrillation: a review
    T D Szucs
    Institute for Social and Preventive Medicine, University of Zurich, Zurich, Switzerland
    J Thromb Haemost 4:1180-5. 2006
    ....
  16. ncbi Developments in influenza vaccination coverage in Italy over five seasons (2001-2006)
    M V Holm
    ECPM Research, European Center of Pharmaceutical Medicine, Basel
    Ann Ig 19:405-15. 2007
    ..Despite of this positive evolution, major effort is still needed to reach WHO objectives for 2010 (75% vaccination coverage rate in the elderly population)...
  17. ncbi Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial
    K J Dedes
    Division of Gynecology, Department of Obstetrics and Gynecology, University Hospital of Zurich, Zurich, Switzerland
    Ann Oncol 18:1493-9. 2007
    ..Routine adjuvant administration of trastuzumab (T) has been implemented in most centers, but its economic impact has not yet been well examined...
  18. ncbi Resource utilisation in the management of dyslipidaemia
    T D Szucs
    Department of Medical Economics, University Hospital, Zurich, Switzerland
    Pharmacoeconomics 14:11-8. 1998
    ....
  19. doi Personalized cancer medicine and the future of pathology
    H Moch
    Institute of Surgical Pathology, University Hospital Zurich, Schmelzbergstrasse 12, Zurich, Switzerland
    Virchows Arch 460:3-8. 2012
    ..The pathology community has the responsibility to lead medical colleagues into embracing this new area of genomic medicine. Without this effort, the discipline of pathology risks losing its key position in molecular tissue diagnostics...
  20. ncbi Medical economic considerations of coronary stenting
    T D Szucs
    Department of Medical Economics, University Hospital, Zurich
    Schweiz Med Wochenschr 129:1701-11. 1999
    ..This paper reviews and summarises the major economic evaluations comparing intracoronary stenting and angioplasty...
  21. ncbi [Costs and cost-effectiveness of Eptifibatide in the treatment of coronary ischemic syndromes. An analysis based on the PURSUIT study]
    T D Szucs
    Hirslanden Research, Seefeldstrasse 214, 8008 Zurich, Switzerland
    Z Kardiol 92:236-44. 2003
    ..Our analysis is based on the clinical results of the PURSUIT study...
  22. ncbi Influenza vaccination coverage rates in 5 European countries: a population-based cross-sectional analysis of the seasons 02/03, 03/04 and 04/05
    D Muller
    Institute for Social and Preventive Medicine, University of Zurich, 8006, Zurich, Switzerland
    Infection 35:308-19. 2007
    ..Influenza continues to be a considerable health problem in Europe. Vaccination is the only preventive measure, reducing mortality and morbidity of influenza in all age groups..
  23. ncbi Medical-economical aspects of high sensitivity C-reactive protein assay for the prediction of coronary heart disease. An analysis in Germany and Italy
    S M Ess
    Department of Medical Economics, University Hospital Zurich, Switzerland
    Ital Heart J 2:181-8. 2001
    ..CONCLUSIONS: Both in the primary and the secondary prevention settings, hs-testing for CRP can better target individuals at higher risk, thus improving outcomes and resulting in a more cost-effective strategy...
  24. ncbi Comparison of resource utilization and long-term quality-of-life outcomes between laparoscopic and conventional colorectal surgery
    E Sokolovic
    Department of Medical Economics, University Hospital Zurich, Switzerland
    Surg Endosc 18:1663-7. 2004
    ..The outcomes of laparosopic and conventional colorectal surgery, with special reference to costs of treatment and patients' quality of life, were compared...
  25. ncbi [On the prognosis of hip fractures. Assessment of mortality after hip fractures by analyzing overlapping segments of longitudinal data]
    R Smektala
    Abteilung fur Unfallchirurgie, Knappschaftskrankenhaus Bochum Langendreer, Universitätsklinik der Ruhr Universität, Bochum
    Unfallchirurg 108:927-8, 930-37. 2005
    ..However, there are no data on the long-term outcome and long-term quality of care...
  26. ncbi Pharmacoeconomics of angiotensin converting enzyme inhibitors in heart failure
    T D Szucs
    Department of Internal Medicine, University of Munich, and the Medical Economics Research Group, Germany
    Am J Hypertens 10:272S-279S. 1997
    ..In addition, analysis of more recent studies of the treatment of fosinopril in patients with mild to moderate CHF have been performed and have proved this newer ACE inhibitor to be cost-saving in these patients...